journal article·2023-09-06

Therapeutic Copolymer from Salicylic Acid and l-Phenylalanine as a Nanosized Drug Carrier for Orthotopic Breast Cancer with Lung Metastasis

Yabin Meng, Shuyan Han, Junqiang Yin, Jun Wu

ACS Applied Materials & Interfaces· Volume 15· Issue 35
Publisher page

Abstract

Nanoparticle (NP)-mediated drug delivery systems are promising for treating various diseases. However, clinical translation has been delayed by a variety of limitations, such as weak drug loading, nonspecific drug leakage, lack of bioactivity, and short blood circulation. These issues are in part due to the unsatisfactory function of biomaterials for nanocarriers. In addition, the synthesis procedures of drug carrier materials, especially polymers, were usually complicated and led to high cost. In this report, a bioactive copolymer of hydroxy acid and amino acid, poly(salicylic acid- co -phenylalanine) (PSP), was developed for the first time via a one-step rapid and facile synthesis strategy. The PSP could self-assemble into NPs (PSP-NPs) to co-load relatively hydrophilic sphingosine kinase 1 inhibitor (PF543 in HCl salt format) and highly hydrophobic paclitaxel (PTX) to form PF543/PTX@PSP-NPs with efficient dual drug loading. Encouragingly, PF543/PTX@PSP-NPs showed long blood circulation, good stability, and high tumor accumulation, leading to significantly enhanced therapeutic effects on breast cancer. Furthermore, PF543/PTX@PSP-NPs could additionally suppress the lung metastasis of breast cancer, and more importantly, the PSP-NPs themselves as therapeutic nanocarriers also showed an anti-breast cancer effect. With these combined advantages, this new polymer and corresponding NPs will provide valuable insights into the development of new functional polymers and nanomedicines for important diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China

School of Biomedical Engineering, Sun Yat-sen University, Shenzhen 518107, China

Department of Nephrology, Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China

Bioscience and Biomedical Engineering Thrust, The Hong Kong University of Science and Technology (Guangzhou), Nansha, Guangzhou 511400, Guangdong China

Division of Life Science, The Hong Kong University of Science and Technology, Hongkong SAR, China

Funding

Science, Technology and Innovation Commission of Shenzhen Municipality · National Natural Science Foundation of China

References (50)

Show source-provided references
1. 10.1016/j.addr.2021.11400610.1016/j.addr.2021.114006 ↗
2. 10.1021/acsami.8b0742510.1021/acsami.8b07425 ↗
3. 10.1002/adfm.20140319010.1002/adfm.201403190 ↗
4. 10.3390/pharmaceutics1302028710.3390/pharmaceutics13020287 ↗
5. 10.1016/j.jhep.2019.09.02510.1016/j.jhep.2019.09.025 ↗
6. 10.1002/adma.20200001310.1002/adma.202000013 ↗
7. 10.1016/j.ctrv.2017.11.00310.1016/j.ctrv.2017.11.003 ↗
8. 10.1002/adfm.20130322210.1002/adfm.201303222 ↗
9. 10.1016/j.bioactmat.2020.04.01010.1016/j.bioactmat.2020.04.010 ↗
10. 10.1002/advs.20180000410.1002/advs.201800004 ↗
11. 10.1002/adhm.20210068310.1002/adhm.202100683 ↗
12. 10.1021/acsabm.2c0012310.1021/acsabm.2c00123 ↗
13. 10.1021/acsabm.2c0000210.1021/acsabm.2c00002 ↗
14. 10.1016/j.apmt.2021.10110410.1016/j.apmt.2021.101104 ↗
15. 10.1002/nano.20200016210.1002/nano.202000162 ↗
16. 10.1016/j.jare.2018.06.00510.1016/j.jare.2018.06.005 ↗
17. 10.1039/D0CS00215A10.1039/D0CS00215A ↗
18. 10.1016/j.nantod.2014.04.00810.1016/j.nantod.2014.04.008 ↗
19. 10.1016/j.cclet.2021.11.07810.1016/j.cclet.2021.11.078 ↗
20. 10.1016/j.cclet.2021.11.05010.1016/j.cclet.2021.11.050 ↗
21. 10.1016/j.msec.2017.12.03610.1016/j.msec.2017.12.036 ↗
22. 10.3389/fphar.2018.0126010.3389/fphar.2018.01260 ↗
23. 10.1007/s11095-020-02922-910.1007/s11095-020-02922-9 ↗
24. 10.1021/acs.biomac.7b0031710.1021/acs.biomac.7b00317 ↗
25. 10.1021/acsami.1c1301310.1021/acsami.1c13013 ↗
26. 10.1002/adfm.20210080510.1002/adfm.202100805 ↗
27. 10.1002/adfm.20190785710.1002/adfm.201907857 ↗
28. 10.1002/adfm.20180864610.1002/adfm.201808646 ↗
29. 10.1039/C5CC07316B10.1039/C5CC07316B ↗
30. 10.1002/advs.20190292610.1002/advs.201902926 ↗
31. 10.1021/acsami.6b1439010.1021/acsami.6b14390 ↗
32. 10.3322/caac.2166010.3322/caac.21660 ↗
33. 10.1002/adma.20190756810.1002/adma.201907568 ↗
34. 10.1016/j.actbio.2020.06.02510.1016/j.actbio.2020.06.025 ↗
35. 10.1158/0008-5472.CAN-18-380310.1158/0008-5472.CAN-18-3803 ↗
36. 10.1038/s41467-019-14218-710.1038/s41467-019-14218-7 ↗
37. 10.3390/cells904088610.3390/cells9040886 ↗
38. 10.1016/j.cellsig.2017.01.02110.1016/j.cellsig.2017.01.021 ↗
39. 10.1002/anie.20170374410.1002/anie.201703744 ↗
40. 10.1021/acs.biomac.2c0015010.1021/acs.biomac.2c00150 ↗
41. 10.1021/acsami.0c1513310.1021/acsami.0c15133 ↗
42. 10.1002/slct.20220461410.1002/slct.202204614 ↗
43. 10.1016/j.actbio.2022.06.02610.1016/j.actbio.2022.06.026 ↗
44. 10.1016/j.cclet.2014.06.02110.1016/j.cclet.2014.06.021 ↗
45. 10.1002/adfm.20191056610.1002/adfm.201910566 ↗
46. 10.1016/j.addr.2019.04.00810.1016/j.addr.2019.04.008 ↗
47. 10.1021/acsami.9b1736310.1021/acsami.9b17363 ↗
48. 10.1021/acsami.7b1843710.1021/acsami.7b18437 ↗
49. 10.1002/adhm.20200039210.1002/adhm.202000392 ↗
50. 10.7150/thno.2320910.7150/thno.23209 ↗